In a significant development for blood cancer patients in England, the NHS has announced the approval of zanubrutinib, a revolutionary ‘take-at-home’ tablet for treating marginal zone lymphoma (MZL). This milestone
In a significant development for blood cancer patients in England, the NHS has announced the approval of zanubrutinib, a revolutionary ‘take-at-home’ tablet for treating marginal zone lymphoma (MZL). This milestone






